Tumor-specific delivery of BSH-3R for boron neutron capture therapy and positron emission tomography imaging in a mouse brain tumor model

Yoshiya Iguchi, Hiroyuki Michiue, Mizuki Kitamatsu, Yuri Hayashi, Fumiaki Takenaka, Tei-ichi Nishiki, Hideki Matsui

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Glioblastoma, a malignant brain tumor with poor disease outcomes, is managed in modern medicine by multimodality therapy. Boron neutron capture therapy (BNCT) is an encouraging treatment under clinical investigation. In malignant cells, BNCT consists of two major factors: neutron radiation and boron uptake. To increase boron uptake in cells, we created a mercapto-closo-undecahydrododecaborate ([B12HnSH]2-2Na+, BSH) fused with a short arginine peptide (1R, 2R, 3R) and checked cellular uptake invitro and invivo. In a mouse brain tumor model, only BSH with at least three arginine domains could penetrate cell membranes of glioma cells invitro and invivo. Furthermore, to monitor the pharmacokinetic properties of these agents invivo, we fused BSH and BSH-3R with 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA); DOTA is a metal chelating agent for labeling positron emission tomography (PET) probe with 64Cu. We administered BSH-DOTA-64Cu and BSH-3R-DOTA-64Cu to the tumor model through a mouse tail vein and determined the drugs' pharmacokinetics by PET imaging. BSH-3R showed a high uptake in the tumor area on PET imaging. We concluded that BSH-3R is the ideal boron compound for clinical use during BNCT and that in developing this compound for clinical use, the BSH-3R PET probe is essential for pharmacokinetic imaging.

Original languageEnglish
Pages (from-to)10-17
Number of pages8
JournalBiomaterials
Volume56
DOIs
Publication statusPublished - Jul 1 2015

Fingerprint

Boron Neutron Capture Therapy
Positron emission tomography
Boron
Brain Neoplasms
Positron-Emission Tomography
Tumors
Brain
Neutrons
Pharmacokinetics
Imaging techniques
Arginine
Acids
Neoplasms
Boron Compounds
Modern 1601-history
Boron compounds
Glioblastoma
Chelating Agents
Glioma
Tail

Keywords

  • Boron neutron capture therapy (BNCT)
  • Brain tumor
  • BSH poly-arginine
  • CPP
  • DOTA
  • Glioma
  • PET
  • TAT

ASJC Scopus subject areas

  • Biomaterials
  • Bioengineering
  • Ceramics and Composites
  • Mechanics of Materials
  • Biophysics

Cite this

Tumor-specific delivery of BSH-3R for boron neutron capture therapy and positron emission tomography imaging in a mouse brain tumor model. / Iguchi, Yoshiya; Michiue, Hiroyuki; Kitamatsu, Mizuki; Hayashi, Yuri; Takenaka, Fumiaki; Nishiki, Tei-ichi; Matsui, Hideki.

In: Biomaterials, Vol. 56, 01.07.2015, p. 10-17.

Research output: Contribution to journalArticle

Iguchi, Yoshiya ; Michiue, Hiroyuki ; Kitamatsu, Mizuki ; Hayashi, Yuri ; Takenaka, Fumiaki ; Nishiki, Tei-ichi ; Matsui, Hideki. / Tumor-specific delivery of BSH-3R for boron neutron capture therapy and positron emission tomography imaging in a mouse brain tumor model. In: Biomaterials. 2015 ; Vol. 56. pp. 10-17.
@article{d251e88962614a21ac35fb634fa11b11,
title = "Tumor-specific delivery of BSH-3R for boron neutron capture therapy and positron emission tomography imaging in a mouse brain tumor model",
abstract = "Glioblastoma, a malignant brain tumor with poor disease outcomes, is managed in modern medicine by multimodality therapy. Boron neutron capture therapy (BNCT) is an encouraging treatment under clinical investigation. In malignant cells, BNCT consists of two major factors: neutron radiation and boron uptake. To increase boron uptake in cells, we created a mercapto-closo-undecahydrododecaborate ([B12HnSH]2-2Na+, BSH) fused with a short arginine peptide (1R, 2R, 3R) and checked cellular uptake invitro and invivo. In a mouse brain tumor model, only BSH with at least three arginine domains could penetrate cell membranes of glioma cells invitro and invivo. Furthermore, to monitor the pharmacokinetic properties of these agents invivo, we fused BSH and BSH-3R with 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA); DOTA is a metal chelating agent for labeling positron emission tomography (PET) probe with 64Cu. We administered BSH-DOTA-64Cu and BSH-3R-DOTA-64Cu to the tumor model through a mouse tail vein and determined the drugs' pharmacokinetics by PET imaging. BSH-3R showed a high uptake in the tumor area on PET imaging. We concluded that BSH-3R is the ideal boron compound for clinical use during BNCT and that in developing this compound for clinical use, the BSH-3R PET probe is essential for pharmacokinetic imaging.",
keywords = "Boron neutron capture therapy (BNCT), Brain tumor, BSH poly-arginine, CPP, DOTA, Glioma, PET, TAT",
author = "Yoshiya Iguchi and Hiroyuki Michiue and Mizuki Kitamatsu and Yuri Hayashi and Fumiaki Takenaka and Tei-ichi Nishiki and Hideki Matsui",
year = "2015",
month = "7",
day = "1",
doi = "10.1016/j.biomaterials.2015.03.061",
language = "English",
volume = "56",
pages = "10--17",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Tumor-specific delivery of BSH-3R for boron neutron capture therapy and positron emission tomography imaging in a mouse brain tumor model

AU - Iguchi, Yoshiya

AU - Michiue, Hiroyuki

AU - Kitamatsu, Mizuki

AU - Hayashi, Yuri

AU - Takenaka, Fumiaki

AU - Nishiki, Tei-ichi

AU - Matsui, Hideki

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Glioblastoma, a malignant brain tumor with poor disease outcomes, is managed in modern medicine by multimodality therapy. Boron neutron capture therapy (BNCT) is an encouraging treatment under clinical investigation. In malignant cells, BNCT consists of two major factors: neutron radiation and boron uptake. To increase boron uptake in cells, we created a mercapto-closo-undecahydrododecaborate ([B12HnSH]2-2Na+, BSH) fused with a short arginine peptide (1R, 2R, 3R) and checked cellular uptake invitro and invivo. In a mouse brain tumor model, only BSH with at least three arginine domains could penetrate cell membranes of glioma cells invitro and invivo. Furthermore, to monitor the pharmacokinetic properties of these agents invivo, we fused BSH and BSH-3R with 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA); DOTA is a metal chelating agent for labeling positron emission tomography (PET) probe with 64Cu. We administered BSH-DOTA-64Cu and BSH-3R-DOTA-64Cu to the tumor model through a mouse tail vein and determined the drugs' pharmacokinetics by PET imaging. BSH-3R showed a high uptake in the tumor area on PET imaging. We concluded that BSH-3R is the ideal boron compound for clinical use during BNCT and that in developing this compound for clinical use, the BSH-3R PET probe is essential for pharmacokinetic imaging.

AB - Glioblastoma, a malignant brain tumor with poor disease outcomes, is managed in modern medicine by multimodality therapy. Boron neutron capture therapy (BNCT) is an encouraging treatment under clinical investigation. In malignant cells, BNCT consists of two major factors: neutron radiation and boron uptake. To increase boron uptake in cells, we created a mercapto-closo-undecahydrododecaborate ([B12HnSH]2-2Na+, BSH) fused with a short arginine peptide (1R, 2R, 3R) and checked cellular uptake invitro and invivo. In a mouse brain tumor model, only BSH with at least three arginine domains could penetrate cell membranes of glioma cells invitro and invivo. Furthermore, to monitor the pharmacokinetic properties of these agents invivo, we fused BSH and BSH-3R with 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA); DOTA is a metal chelating agent for labeling positron emission tomography (PET) probe with 64Cu. We administered BSH-DOTA-64Cu and BSH-3R-DOTA-64Cu to the tumor model through a mouse tail vein and determined the drugs' pharmacokinetics by PET imaging. BSH-3R showed a high uptake in the tumor area on PET imaging. We concluded that BSH-3R is the ideal boron compound for clinical use during BNCT and that in developing this compound for clinical use, the BSH-3R PET probe is essential for pharmacokinetic imaging.

KW - Boron neutron capture therapy (BNCT)

KW - Brain tumor

KW - BSH poly-arginine

KW - CPP

KW - DOTA

KW - Glioma

KW - PET

KW - TAT

UR - http://www.scopus.com/inward/record.url?scp=84928385792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928385792&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2015.03.061

DO - 10.1016/j.biomaterials.2015.03.061

M3 - Article

C2 - 25934274

AN - SCOPUS:84928385792

VL - 56

SP - 10

EP - 17

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

ER -